CARLSBAD, Calif.--(BUSINESS WIRE)--May 19, 2003-- The Immune Response Corporation (Nasdaq:IMNR - News) today announced the forthcoming publication of results from a trial involving REMUNE® by the peer-reviewed journal AIDS. The trial, while enrolling only a limited number of patients, concluded that vaccination with REMUNE® increased HIV-1 specific immune response in chronic HIV patients receiving suppressive antiretroviral therapy (ART). Its authors, led by Dr. Bruce Walker, director of the AIDS Research Center at Massachusetts General Hospital, affiliated with Harvard Medical School, stated that further studies were warranted in light of these findings.
ADVERTISEMENT
"We welcome the intense peer review that preceded the publication of these results," commented John N. Bonfiglio, Ph.D., chief executive officer of The Immune Response Corporation. "Our newly established Scientific Advisory Board will use this data to help design future trials of REMUNE® in order to help accomplish our mission of establishing REMUNE®'s clinical benefit."
Specifically, the trial -- which was investigator-initiated and designed, double blinded and placebo-controlled -- demonstrated the induction of HIV-specific lymphocyte proliferation in all the chronically infected subjects who received REMUNE® and in none of those who received placebo. A total of 10 subjects participated, all of whom had viral loads controlled to less than 500 copies/ml for at least six months and CD4 cell counts of greater than 250 cells/mrn before starting ART.
ADVERTISEMENT
"We welcome the intense peer review that preceded the publication of these results," commented John N. Bonfiglio, Ph.D., chief executive officer of The Immune Response Corporation. "Our newly established Scientific Advisory Board will use this data to help design future trials of REMUNE® in order to help accomplish our mission of establishing REMUNE®'s clinical benefit."
Specifically, the trial -- which was investigator-initiated and designed, double blinded and placebo-controlled -- demonstrated the induction of HIV-specific lymphocyte proliferation in all the chronically infected subjects who received REMUNE® and in none of those who received placebo. A total of 10 subjects participated, all of whom had viral loads controlled to less than 500 copies/ml for at least six months and CD4 cell counts of greater than 250 cells/mrn before starting ART.
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
